News | Implantable Cardiac Monitor (ICM) | July 16, 2015

Medtronic Initiates Study of In-Office Insertion of Reveal Linq Cardiac Monitor

RIO 2 study evaluates safety and effectiveness of moving insertion procedure from hospital to office setting

Medtronic, Reveal Linq ICM, in-office insertion, RIO 2 study

July 16, 2015 - Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal LINQ In-Office 2 (RIO 2) Study. One of the world's smallest cardiac monitors, the Reveal LINQ insertable cardiac monitor (ICM) was successfully implanted in an office setting at Scripps Clinic in La Jolla, California, by cardiologist John Rogers, M.D. The RIO 2 study will determine if the procedure, performed in an in-office setting, is as safe as procedures performed in a traditional hospital setting - such as an operating room, cardiac catheterization laboratory or electrophysiology laboratory.

"Studies such as RIO 2 may enable physicians to provide their patients with even greater access to the latest diagnostic tools and therapies," said Rogers. "In-office procedures have the potential to help patients and reduce costs to the healthcare system."

RIO 2 is enrolling approximately 540 patients in 30 centers across the United States in a two-arm, prospective, un-blinded study in which patients will be randomized 1:1 to either receive the Reveal LINQ ICM in an office setting or in a traditional hospital setting. Patients will be followed for approximately three months and evaluated for procedure and device-related complications, and also for procedure time and resources required to perform the procedure.

The RIO 2 study also is enrolling approximately 150 patients in 15 centers across Europe, Australia and Canada. This observational study will examine clinical evidence to support moving the LINQ insertion procedure from the traditional hospital setting to new locations within the hospital, or "out-of-lab."

Cleared by the U.S. Food and Drug Administration (FDA) in 2014, the Reveal LINQ ICM system is the newest generation of ICM and the smallest cardiac monitor available (~1 cc, or one-third the size of a AAA battery). The device is placed under the skin of the chest using a minimally invasive insertion procedure and allows physicians to continuously and wirelessly monitor a patient's heart through the Carelink Network for up to three years. Common uses include monitoring syncope (fainting) patients for potential episodes of bradycardia (slow heartbeat), monitoring patients who have had cryptogenic strokes (strokes of unknown cause) for possible episodes of atrial fibrillation, and monitoring patients suffering from intermittent chest palpitations for potential episodes of atrial or ventricular arrhythmias.

For more information:

Related Content

First ICM device with remote programming paired with dual-stage arrhythmia detection algorithm
News | Implantable Cardiac Monitor (ICM) | June 29, 2020
June 29, 2020 — Boston Scientific received U.S.
Researchers File Patent for Tiny Blood Flow Sensor

Image courtesy of Flinders University

News | Implantable Cardiac Monitor (ICM) | July 09, 2019
South Australian researchers are developing a tiny fiber-optic sensor, which has the potential to change the way blood...
Biotronik Launches Biomonitor III Injectable Cardiac Monitor in the CE Region
News | Implantable Cardiac Monitor (ICM) | July 01, 2019
Biotronik announced the market release of its new injectable cardiac monitor (ICM), Biomonitor III, following approval...
Abbott Launches Next-generation Confirm RX Implantable Cardiac Monitor
News | Implantable Cardiac Monitor (ICM) | May 06, 2019
Abbott announced the launch of a new, smarter heart monitor for better arrhythmia detection — positive news for people...
The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack.

 The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack. 

Technology | Implantable Cardiac Monitor (ICM) | May 09, 2018
 May 9, 2018 — The U.S.
Abbott SJM St. Jude Confirm RX implantable cardiac monitor (ICM).

The Abbott Confirm RX implantable cardiac monitor (ICM) is smaller than a computer thumb-drive and in implanted in a simple in-office procedure just under the skin.

Technology | Implantable Cardiac Monitor (ICM) | October 23, 2017
October 23, 2017 – The U.S.
Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM) | April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM) | March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ
News | Implantable Cardiac Monitor (ICM) | March 14, 2017
Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM) | February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...